EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer

Yifan Liu, Yanjun Xu, Wenrong Yu, Chenxi Gao, Sirui Wu, Hongjun Jin, Mengze Xu

Pharmaceutics · 09.11.2026 · 18 (11) · 1448

DOI: 10.3390/pharmaceutics18111448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 09.11.2026. Verfasst von Yifan Liu und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, the Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor necrosis factor receptor 2 (TNFR2) is a pivotal immune checkpoint that is highly expressed within the immunosuppressive tumor microenvironment (TME), particularly on regulatory T cells (Tregs). The P20 peptide specifically binds TNFR2, but its rapid enzymatic degradation in vivo severely limits its clinical translation as an imaging tracer.

Methods

Here, we developed a P20-conjugated lipid nanoprobe (DPP) via thin-film hydration and systematically evaluated its physicochemical properties, receptor-binding specificity, biosafety, and in vivo positron emission tomography (PET)/computed tomography (CT) imaging performance in male C57BL/6J mice bearing subcutaneous MC38 wild-type (WT) or TNFR2-knockout (KO) colon tumors.

Results

DPP exhibited a near-spherical morphology, a predominant particle-size distribution peak at approximately 125.6 nm, a negative surface charge, and relatively stable hydrodynamic diameters over 7 days. In vitro assays supported TNFR2-associated cellular recognition and showed negligible cytotoxicity under the tested conditions. Micro-PET/CT imaging revealed that DPP markedly improved tumor retention (tumor SUVmean at 4 h: 0.577 ± 0.314) compared with free P20 (SUVmean at 4 h: 0.065 ± 0.011; n = 6 per group; two-sided Welch’s unpaired t-test with Benjamini–Hochberg correction, adjusted q = 0.010298) in MC38-WT tumors. Tumor SUVmean was higher in WT than in KO tumors at 7 h (0.677 ± 0.181 vs. 0.381 ± 0.191; p = 0.02942) and 12 h (0.428 ± 0.121 vs. 0.224 ± 0.108; p = 0.01588), with both adjusted q values equal to 0.05885 (n = 6 and n = 5, respectively). Notably, tumor-to-muscle uptake ratios were also higher in WT tumors at 7 h (13.11 ± 5.10 vs. 6.86 ± 2.97; p = 0.03459; adjusted q = 0.13836).

Conclusions

These results demonstrate that the liposomal formulation enhances tumor-associated uptake of the P20-based tracer, while TNFR2-dependent uptake and the non-invasive monitoring of Treg compartments remain to be validated.

Förderung

  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • the Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund
  • the National Key R&D Program of China
  • the Key Realm R&D Program of Guangdong Province
  • Macao Science and Technology Development Fund
  • Leading Yang Technology (Shenzhen) Co., Ltd.
  • Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund

Zitieren

APA

Liu, Y., Xu, Y., Yu, W., Gao, C., Wu, S., Jin, H., & Xu, M. (2026). TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer. Pharmaceutics, 18(11), 1448. https://doi.org/10.3390/pharmaceutics18111448

Vancouver

Liu Y, Xu Y, Yu W, Gao C, Wu S, Jin H, et al. TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer. Pharmaceutics. 2026;18(11):1448. doi:10.3390/pharmaceutics18111448

BibTeX
@article{Liu2026,
  author = {Liu, Yifan and Xu, Yanjun and Yu, Wenrong and Gao, Chenxi and Wu, Sirui and Jin, Hongjun and Xu, Mengze},
  title = {TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1448},
  doi = {10.3390/pharmaceutics18111448}
}
Kostenlos starten →